Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: biosimilar human protein therapeutics - Inbiopro Solutions

Next Previous
Drug Profile

Research programme: biosimilar human protein therapeutics - Inbiopro Solutions

Alternative Names: Biosimilars- Inbiopro Solutions; IBPB 004IG; IBPB 005ET; IBPB 006IA; IBPB 007IL; IBPB 008IG

Latest Information Update: 16 Aug 2013

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inbiopro Solutions
  • Class Interleukins; Proteins
  • Mechanism of Action Bone marrow cell stimulants; Cytotoxic T lymphocyte stimulants; Interleukin 1 receptor antagonists; Leukocyte stimulants; Natural killer cell stimulants; Neutrophil stimulants; Plasmin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Acute myeloid leukaemia; Chronic granulomatous disease; Chronic hepatitis; Hairy cell leukaemia; Myocardial infarction; Neutropenia; Osteoporosis; Rheumatoid arthritis; Stroke

Most Recent Events

  • 31 Dec 2009 Suspended - Preclinical for Acute myeloid leukaemia (adjunctive therapy) and Neutropenia (adjunctive therapy)in India (unspecified route)
  • 31 Dec 2009 Suspended - Preclinical for Myocardial infarction and Stroke in India (unspecified route)
  • 30 Jun 2009 Suspended - Preclinical for Chronic hepatitis (B or C) and Hairy cell leukaemia in India (unspecified route)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top